Practical use of the Framingham risk score in primary prevention: Canadian perspective

N John Bosomworth, N John Bosomworth

Abstract

Objective: To review the 2009 Canadian Cardiovascular Society guidelines and provide practical recommendations for physicians.

Sources of information: Initial review of the references provided with the guidelines led to a search of the PubMed, ACP Journal Club, and Cochrane databases using the key words primary prevention and statin for English language clinical trials, randomized controlled trials, meta-analyses, and reviews conducted with human participants. References from appropriate retrieved articles were also reviewed.

Main message: The guidelines outline low-density lipoprotein cholesterol (LDL-C) thresholds and targets to inform optimal use of statins in the primary prevention of cardiovascular disease (CVD). Family history of CVD and levels of high-sensitivity C-reactive protein (hsCRP) are risk modifiers in calculating the risk score with the new recommendations. An electronic calculator has been developed to facilitate increased uptake of these guidelines. Large numbers of asymptomatic people, particularly the elderly, will become eligible for statin therapy according to these new guidelines. Poor uptake by physicians and patients might result from the need for repeated testing of hsCRP and LDL-C levels in people who do not perceive themselves to be ill. Controversy persists concerning the role of hsCRP in the reclassification of CVD risk, and the concept of treating LDL-C to target has never been tested as an independent variable in a randomized trial. As two-thirds of the LDL-C lowering achieved by a statin occurs at the initial dose, it might be possible to achieve considerable CVD risk reduction for those at risk by treating initially with a mid-dose statin without LDL-C follow-up.

Conclusion: A simplified approach might appeal to patients or physicians who find current guidelines too complex, cumbersome, or costly. Success in getting high-risk patients to take statins is key to achieving improved CVD mortality reduction.

References

    1. Genest J, McPherson R, Frohlich J, Anderson T, Campbell N, Carpentier A, et al. 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult—2009 recommendations. Can J Cardiol. 2009;25(10):567–79.
    1. D’Agostino RB, Sr, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, et al. General cardiovascular risk profile for use in primary care: the Framingham heart study. Circulation. 2008;117(6):743–53. Epub 2008 Jan 22.
    1. Grover SA, Lowensteyn I, Joseph L, Kaouache M, Marchand S, Coupal L, et al. Cardiovascular Health Evaluation to Improve Compliance and Knowledge Among Uninformed Patients (CHECK-UP) Study Group. Patient knowledge of coronary risk profile improves the effectiveness of dyslipidemia therapy: the CHECK-UP study: a randomized controlled trial. Arch Intern Med. 2007;167(21):2296–303.
    1. Ray KK, Seshasai SR, Erqou S, Sever P, Jukema W, Ford I, et al. Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65,229 participants. Arch Intern Med. 2010;170(12):1024–31.
    1. Pletcher MJ, Lazar L, Bibbins-Domingo K, Moran A, Rodondl N, Coxson P, et al. Comparing impact and cost-effectiveness of primary prevention strategies for lipid lowering. Ann Intern Med. 2009;150(4):243–54.
    1. Moride Y, Hegele RA, Langer A, McPherson R, Miller DB, Rinfret S. Clinical and public health assessment of benefits and risks of statins in primary prevention of coronary events: resolved and unresolved issues. Can J Cardiol. 2008;24(4):293–300.
    1. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Cholesterol Treatment Trialists’ (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267–78. 9493. Epub 2005 Sep 27. Erratum in: Lancet 2005;366(9494):1358. Erratum in: Lancet 2008;371(9630):2084.
    1. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM, Jr, Kastelein JJ, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195–207. Epub 2008 Nov 9.
    1. Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361(9364):1149–58.
    1. De Lorgeril M, Salen P, Abramson J, Dodin S, Hamazaki T, Kostucki W, et al. Cholesterol lowering, cardiovascular diseases, and the rosuvastatin-JUPITER controversy: a critical reappraisal. Arch Intern Med. 2010;170(12):1032–6.
    1. Chan PS, Nallamothu BK, Hayward RA. Rosuvastatin in patients with elevated C-reactive protein [letter] N Engl J Med. 2009;360(10):1039.
    1. Kappagoda CT, Amsterdam EA. Another look at the results of the JUPITER trial. Am J Cardiol. 2009;104(11):1603–5. Epub 2009 Oct 14.
    1. Rose G. Sick individuals and sick populations. Int J Epidemiol. 2001;30(3):427–32.
    1. Zulman DM, Vigan S, Omenn GS, Hayward RA. The relative merits of population-based and targeted prevention strategies. Milbank Q. 2008;86(4):557–80.
    1. Hippisley-Cox J, Coupland C. Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database. BMJ. 2010;340:c2197. doi: 10.1136/bmj.c2197.
    1. Kearns AK, Bilbie CL, Clarkson PM, White CM, Sewright KA, O’Fallon KS, et al. The creatine kinase response to eccentric exercise with atorvastatin 10 mg or 80 mg. Atherosclerosis. 2008;200(1):121–5. Epub 2008 Feb 7.
    1. Sinzinger H, O’Grady J. Professional athletes suffering from familial hyper-cholesterolaemia rarely tolerate statin treatment because of muscular problems. Br J Clin Pharmacol. 2004;57(4):525–8.
    1. Thomas M, Mann J. Increased thrombotic vascular events after change of statin. Lancet. 1998;352(9143):1830–1.
    1. Josan K, Majumdar SR, McAlister FA. The efficacy and safety of intensive statin therapy: a meta-analysis of randomized trials. CMAJ. 2008;178(5):576–84.
    1. Brugts JJ, Yetgin T, Hoeks SE, Gotto AM, Shepherd J, Westendorp RG, et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ. 2009;338:b2376. doi: 10.1136/bmj.b2376.
    1. Abramson J, Wright JM. Are lipid-lowering guidelines evidence-based? Lancet. 2007;369(9557):168–9.
    1. Bulugahapitiya U, Siyambalapitiya S, Sithole J, Idris I. Is diabetes a coronary risk equivalent? Systematic review and meta-analysis. Diabet Med. 2009;26(2):142–8.
    1. Hayward RA, Krumholz HM, Zulman DM, Timbie JW, Vijan S. Optimizing statin treatment for primary prevention of coronary artery disease. Ann Intern Med. 2010;152(2):69–77.
    1. Hayward RA, Hofer TP, Vijan S. Narrative review: lack of evidence for recommended low-density lipoprotein treatment targets: a solvable problem. Ann Intern Med. 2006;145(7):520–30.
    1. Hayward RA. All-or-nothing treatment targets make bad performance measures. Am J Manag Care. 2007;13(3):126–8.
    1. Shepherd J. Resource management in prevention of coronary heart disease: optimising prescription of lipid-lowering drugs. Lancet. 2002;359(9325):2271–3.
    1. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ. 2003;326(7404):1423–7.
    1. Jones PH. Statins: a case for higher, individualized starting doses. Cleve Clin J Med. 2005;72(9):811–6.
    1. Petrella RJ, Merikle EA. A retrospective analysis of the prevalence and treatment of hypertension and dyslipidemia in southwestern Ontario, Canada. Clin Ther. 2008;30(6):1145–54.
    1. McCormack JP, Allan GM. Measuring hsCRP—an important part of a comprehensive risk profile or a clinically redundant practice? PLoS Med. 2010;7(2):e1000196.
    1. Shah T, Casas JP, Cooper JA, Tzoulaki I, Sofat R, McCormack V, et al. Critical appraisal of CRP measurement for the prediction of coronary heart disease events: new data and systematic review of 31 prospective cohorts. Int J Epidemiol. 2009;38(1):217–31. Epub 2008 Oct 17. Erratum in: Int J Epidemiol 2009;38(3):890.
    1. Miller M, Zahn M, Havas S. High attributable risk of elevated C-reactive protein level to conventional coronary heart disease risk factors: the Third National Health and Nutrition Examination Survey. Arch Intern Med. 2005;165(18):2063–8.
    1. Ridker PM, McFayden JG, Fonseca FA, Genest J, Gotto AM, Kastelein JJ, et al. Number needed to treat among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: Justification for the Use of Statins in Prevention: an Interventional Trial Evaluating Rosuvastatin (JUPITER) Circ Cardiovasc Qual Outcomes. 2009;2(6):616–23. Epub 2009 Sep 22.
    1. Buckley DI, Fu R, Freeman M, Rogers K, Helfand M. C-reactive protein as a risk factor for coronary disease: a systematic review and meta-analysis for the US Preventive Services Task Force. Ann Intern Med. 2009;151(7):483–95.
    1. Cannon CP, Braunwald E, McCabe CH, Rader D, Rouleau JL, Belder R, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350(15):1495–504. Epub 2004 Mar 8. Erratum in: N Engl J Med 2006;354(7):778.
    1. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352(14):1425–35. Epub 2005 Mar 8.
    1. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hyper-cholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333(20):1301–7.
    1. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT) JAMA. 2002;288(23):2998–3007.
    1. Ridker PM, Paynter NP, Rifai N, Gaziano JM, Cook NR. C-reactive protein and family history improve global cardiovascular risk prediction: the Reynolds Risk Score for men. Circulation. 2008;118(22):2243–51. Epub 2008 Nov 9.
    1. Perreault S, Dragomir A, Blais L, Bérard A, Lalonde L, White M, et al. Impact of better adherence to statin agents in the primary prevention of coronary artery disease. Eur J Clin Pharmacol. 2009;65(10):1013–24. Epub 2009 Jun 16.
    1. US Preventive Services Task Force . Aspirin for the prevention of cardiovascular disease: clinical summary. Rockville, MD: Agency for Healthcare Research and Quality; 2009. Available from: . Accessed 2010 Jan 30.
    1. Dormuth CR, Schneeweiss S, Brookhart AM, Carney G, Bassett K, Adams S, et al. Frequency and predictors of tablet splitting in statin prescriptions: a population-based analysis. Open Medicine. 2008;2(3):74–82.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe